Vicore Pharma Holding AB (publ)

$10.90-1.09%($-0.12)
TickerSpark Score
53/100
Mixed
53
Valuation
40
Profitability
10
Growth
84
Health
80
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VICO.ST research report →

52-Week Range53% of range
Low $7.35
Current $10.90
High $14.10

Companywww.vicorepharma.com

Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19; and VP02, a formulation and delivery route for an existing immunomodulatory compound, which is preclinical trials to treat patients with IPF. It has a cooperation and development agreement with Emeriti Bio AB; license agreement with Nanologica AB (publ); and a collaboration agreement with Alex Therapeutics AB for the development and clinical validation of a digital therapeutic (DTx) built on the Alex DTx platform.

CEO
Ahmed S. Mousa
IPO
2015
Employees
33
HQ
Stockholm, SE

Price Chart

+27.63% · this period
$13.34$10.34$7.35May 16Nov 13May 21

Valuation

Market Cap
$2.60B
P/E
-6.47
P/S
737.26
P/B
3.10
EV/EBITDA
-4.51
Div Yield
0.00%

Profitability

Gross Margin
78.45%
Op Margin
-13790.90%
Net Margin
-13454.92%
ROE
-50.04%
ROIC
-48.99%

Growth & Income

Revenue
$3.82M · -96.51%
Net Income
$-477,474,000 · -183.14%
EPS
$-1.99 · -165.33%
Op Income
$-454,445,000
FCF YoY
100.00%

Performance & Tape

52W High
$14.10
52W Low
$7.35
50D MA
$10.26
200D MA
$10.80
Beta
-0.08
Avg Volume
548.67K

Get TickerSpark's AI analysis on VICO.ST

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Our VICO.ST Coverage

We haven't published any research on VICO.ST yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate VICO.ST Report →

Similar Companies